In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.1% to 8,873 points.
Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:
Image source: Getty Images
Brainchip Holdings Ltd (ASX: BRN)
The Brainchip share price is down 2% to 15.2 cents. This semiconductor company's shares have been under heavy selling pressure since the release of another disappointing quarterly update. Despite entering the commercialisation stage a few years ago, Brainchip revealed cash receipts of just US$0.4 million for the three months ended 31 December. Given that its market capitalisation is still $350 million, it wouldn't be surprising if the selling continues if there's no meaningful improvement in its sales.
Credit Corp Group Ltd (ASX: CCP)
The Credit Corp share price is down over 15% to $12.07. Investors have been selling this debt collector's shares following the release of its half-year results. Credit Corp posted a 4% increase in revenue to $283.6 million and flat net profit after tax of $44.1 million. Looking ahead, management believes it can still achieve its net profit after tax guidance range of $100 million to $110 million. Investors don't appear confident it will get there.
Graincorp Ltd (ASX: GNC)
The Graincorp share price is down 3% to $6.00. This may have been driven by a broker note out of Macquarie Group Ltd (ASX: MQG). This morning, the broker downgraded the grain exporter's shares to a neutral rating (from outperform) with a reduced price target of $6.60 (from $8.30). Macquarie appears concerned that margins could remain under pressure in the near term, which could weigh on its earnings growth.
Neuren Pharmaceuticals Ltd (ASX: NEU)
The Neuren Pharmaceuticals share price is down 12% to $14.25. This morning, Neuren Pharmaceuticals revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative trend vote on its marketing authorisation application for trofinetide in the European market. Neuren's CEO, Jon Pilcher, commented: "Given the totality of experience with trofinetide in clinical trials and real world use over many years, this negative trend vote is frustrating for us and the Rett syndrome community in the EU. We fully support Acadia's intention to seek re-examination of the CHMP opinion in February, if necessary."
